Cambridge-based Aura Biosciences, Inc. is a biotechnology firm that specializes in pioneering cancer therapies. They are at the forefront of developing a virus-like drug conjugates (VDC) technology platform that addresses the treatment of tumors with high unmet demand in ocular and urologic oncology. Their flagship product, AU-011, a candidate VDC, is currently undergoing Phase III clinical trials for the treatment of primary choroidal melanoma. In addition, Aura Biosciences is working on other ocular oncology indications for AU-011, including choroidal metastases, and currently in Phase 2 dose-escalation trial. Founded in 2009, the biotech firm continues to disrupt the industry with its innovative research and is headquartered in Cambridge, Massachusetts.
Aura Biosciences's ticker is AURA
The company's shares trade on the LSE stock exchange
They are based in Carlton, Australia
There are 1-10 employees working at Aura Biosciences
It is aurabiosciences.com
Aura Biosciences is in the Energy sector